Grufity logo
Grufity logo
INMB

INMB - Inmune Bio Inc Stock Price, Fair Value and News

$1.27-0.01 (-0.78%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

82/100

INMB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

82/100

INMB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

INMB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INMB Price Action

Last 7 days

3.2%

Last 30 days

-17.4%

Trailing 12 Months

-83.4%

INMB RSI Chart

INMB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INMB Valuation

Market Cap

34.0M

Price/Earnings (Trailing)

-0.82

Price/Sales (Trailing)

680.58

EV/EBITDA

0.27

Price/Free Cashflow

-1.68

INMB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

INMB Fundamentals

INMB Revenue

INMB Earnings

Earnings (TTM)

-41.6M

Earnings Growth (Yr)

44.55%

Earnings Growth (Qtr)

-2.58%

INMB Profitability

EBT Margin

91866.00%

Return on Equity

-211.95%

Return on Assets

-161.1%

Free Cashflow Yield

-59.37%

INMB Investor Care

Shares Dilution (1Y)

15.94%

Diluted EPS (TTM)

-1.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
202532.0K--50.0K
2024131.0K85.0K-14.0K
2023249.0K279.0K224.0K155.0K
2022340.0K356.0K440.0K374.0K
202153.5K96.0K138.5K181.0K
2020---11.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Inmune Bio Inc

INMB
INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
 CEO
 WEBSITEinmunebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES10

Inmune Bio Inc Frequently Asked Questions

INMB is the stock ticker symbol of Inmune Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Inmune Bio Inc is 34.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, INMB's PE ratio (Price to Earnings) is -0.82 and Price to Sales (PS) ratio is 680.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INMB PE ratio will change depending on the future growth rate expectations of investors.